Novartis AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2003-03-31
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Novartis
- Registration Number
- NCT00057265
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
- Conditions
- Colorectal NeoplasmsColonic NeoplasmsRectal Neoplasms
- Interventions
- First Posted Date
- 2003-03-14
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1168
- Registration Number
- NCT00056459
- Locations
- ๐บ๐ธ
Alabama Hematology/Oncology, Birmingham, Alabama, United States
๐บ๐ธPalo Verde Hematology & Oncology, Glendale, Arizona, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
- Conditions
- Breast CancerMultiple MyelomaProstate Cancer
- First Posted Date
- 2002-01-10
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 500
- Registration Number
- NCT00029224
- Locations
- ๐บ๐ธ
Stockton Hematology Oncology Medical Group, Stockton, California, United States
๐บ๐ธOsceola Cancer Center, Kissimmee, Florida, United States
๐บ๐ธNevada Cancer Center, Las Vegas, Nevada, United States
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00002394
- Locations
- ๐บ๐ธ
Therafirst Med Ctr, Fort Lauderdale, Florida, United States
๐บ๐ธAssociates in Research, Fort Myers, Florida, United States
๐บ๐ธClireco Inc, Tamarac, Florida, United States
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
- Conditions
- Alzheimer DiseaseCognition Disorders
- First Posted Date
- 1999-11-01
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Registration Number
- NCT00000174
- Locations
- ๐บ๐ธ
Medici Research Centers, Peoria, Arizona, United States
๐บ๐ธUniversity of California, Irvine, Orange, California, United States
๐บ๐ธUniversity of Colorado Health Sciences Center, Denver, Colorado, United States